After 2 years of follow-up, the pooled results from both cohorts showed that continued clinical benefit was observed with nivolumab plus ipilimumab in all patients, including those patients with tumor PD-L1 expression ≥1% and ≥50%, regardless of EGFR status, smoking status, or histology. Here, CD274 is linked to neoplasm.